-
1
-
-
0030317629
-
Protease inhibitors for HIV infection
-
Bartlett JG. Protease inhibitors for HIV infection [Editorial]. Ann Intern Med. 1996;124:1086-8.
-
(1996)
Ann Intern Med
, vol.124
, pp. 1086-1088
-
-
Bartlett, J.G.1
-
2
-
-
0029777564
-
Therapy for human immunodeficiency virus infection - What have we learned?
-
Corey L, Holmes KK. Therapy for human immunodeficiency virus infection - what have we learned? [Editorial] N Engl J Med. 1996;335:1142-4.
-
(1996)
N Engl J Med
, vol.335
, pp. 1142-1144
-
-
Corey, L.1
Holmes, K.K.2
-
3
-
-
0031024623
-
HIV-1 protease inhibitors. A review for clinicians
-
Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145-53.
-
(1997)
JAMA
, vol.277
, pp. 145-153
-
-
Deeks, S.G.1
Smith, M.2
Holodniy, M.3
Kahn, J.O.4
-
4
-
-
24544454457
-
Merck's rush to bring drug to market causes bottleneck
-
5 November
-
Tanouye E. Merck's rush to bring drug to market causes bottleneck. Wall Street Journal. 5 November 1996: A1, A6.
-
(1996)
Wall Street Journal
-
-
Tanouye, E.1
-
5
-
-
0343341426
-
Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine
-
Washington, DC
-
Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [Abstract]. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC: 1996:LB7.
-
(1996)
Third Conference on Retroviruses and Opportunistic Infections
-
-
Gulick, R.1
Mellors, J.2
Havlir, D.3
Eron, J.4
Gonzalez, C.5
McMahon, D.6
-
7
-
-
0343471516
-
Urinary stones in HIV-1 positive patients treated with indinavir
-
Daudon M, Estépa L, Viard JP, Joy D, Jungers P. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet. 1997;349:1294-5.
-
(1997)
Lancet
, vol.349
, pp. 1294-1295
-
-
Daudon, M.1
Estépa, L.2
Viard, J.P.3
Joy, D.4
Jungers, P.5
-
10
-
-
0027969994
-
L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor
-
Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem. 1994;14:3443-51.
-
(1994)
J Med Chem
, vol.14
, pp. 3443-3451
-
-
Dorsey, B.D.1
Levin, R.B.2
McDaniel, S.L.3
Vacca, J.P.4
Guare, J.P.5
Darke, P.L.6
-
13
-
-
0029073966
-
pH-dependent oral absorption of I-735,524, a potent HIV protease inhibitor, in rats and dogs
-
Lin JH, Chen IW, Vastag KJ, Ostovic D. pH-dependent oral absorption of I-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos. 1995;23:730-5.
-
(1995)
Drug Metab Dispos
, vol.23
, pp. 730-735
-
-
Lin, J.H.1
Chen, I.W.2
Vastag, K.J.3
Ostovic, D.4
-
14
-
-
0028868234
-
Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine
-
Balani SH, Arison BH, Mathai L, Kauffman LR, Miller RR, Sterns RA, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos. 1995;23:266-70.
-
(1995)
Drug Metab Dispos
, vol.23
, pp. 266-270
-
-
Balani, S.H.1
Arison, B.H.2
Mathai, L.3
Kauffman, L.R.4
Miller, R.R.5
Sterns, R.A.6
-
15
-
-
0026760992
-
The pathogenesis and treatment of kidney stones
-
Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992;327:1141-52.
-
(1992)
N Engl J Med
, vol.327
, pp. 1141-1152
-
-
Coe, F.L.1
Parks, J.H.2
Asplin, J.R.3
-
16
-
-
0026607425
-
Renal calculi: Pathogenesis, diagnosis, and medical therapy
-
Preminger GM. Renal calculi: pathogenesis, diagnosis, and medical therapy. Semin Nephrol. 1992;12:200-16.
-
(1992)
Semin Nephrol
, vol.12
, pp. 200-216
-
-
Preminger, G.M.1
-
17
-
-
0023462667
-
Drug-induced renal stones: Incidence, clinical expression and stone analysis
-
Rapado A, Traba ML, Caycho C, Cifuentes-Delatte L. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol. 1987;58:25-9
-
(1987)
Contrib Nephrol
, vol.58
, pp. 25-29
-
-
Rapado, A.1
Traba, M.L.2
Caycho, C.3
Cifuentes-Delatte, L.4
-
18
-
-
0023885935
-
Acyclovir-induced renal failure. Clinical course and histology
-
Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988;84:1067-72.
-
(1988)
Am J Med
, vol.84
, pp. 1067-1072
-
-
Sawyer, M.H.1
Webb, D.E.2
Balow, J.E.3
Straus, S.E.4
-
19
-
-
0029027221
-
Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient
-
Farina LA, Palou Redorta J, Chechile Toniolo G. Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient. Arch Esp Urol. 1995;48:418-19.
-
(1995)
Arch Esp Urol
, vol.48
, pp. 418-419
-
-
Farina, L.A.1
Palou Redorta, J.2
Chechile Toniolo, G.3
-
20
-
-
0004225114
-
-
Bethesda, MD: American Society of Health-System Pharmacists
-
McEvoy GK, ed. Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 1996.
-
(1996)
Drug Information
-
-
McEvoy, G.K.1
-
21
-
-
0029742853
-
Drug interactions in patients infected with human immunodeficiency virus
-
Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:685-93.
-
(1996)
Clin Infect Dis
, vol.23
, pp. 685-693
-
-
Piscitelli, S.C.1
Flexner, C.2
Minor, J.R.3
Polis, M.A.4
Masur, H.5
|